发现了作为模式选择性TRPV1抗剂的N-(1,4-佐-3-one) 尿素类似物
Guocheng Huang1, Aeran Jung1, Li-Xuan Li1
1Laboratory of Medicinal Chemistry, College of Pharmacy, Seoul National University, Seoul 08826, South Korea.
Bioorganic & medicinal chemistry letters
|April 8, 2024
概括
研究人员开发了新型模式选择性TRPV1抗剂,如化合物36,以尽量减少副作用. 这些化合物选择性地阻断素激活,为临床TRPV1抗剂的开发提供了有前途的进展.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 寻求暂时受体潜在瓦尼洛伊德1 (TRPV1) 抗剂来减轻不良影响.
- 现有的高亲和度对抗剂在所有激活模式中都表现出完全的对抗性,可能导致诸如高温症之类的副作用.
研究的目的:
- 发现具有减少脱效应的选择性TRPV1抗剂.
- 优化化合物2以提高选择性和功效.
主要方法:
- 结构-活性关系 (SAR) 研究涉及对1,4-甲-3-one类似物A和C区域的修改.
- 在体外测试以评估素和质子激活的对抗性.
- 分子建模以阐明结合相互作用.
主要成果:
- 修改C区域的t-丁和 thiazole 部分产生的强效和模式选择性对抗剂.
- 化合物36被证明具有强效 (IC50 = 2.31 nM) 和素选择性对抗作用.
- 与素激活相比,化合物36需要超过1000倍的度来抑制质子激活.
- 分子建模揭示了关键相互作用 (π-π 和键),对化合物36的结合至关重要.
结论:
- 模式选择性TRPV1抗剂36通过系统优化化合物2成功开发.
- 化合物36在临床开发中表现出有希望的特征,可能将与非选择性TRPV1抗剂相关的副作用降到最低.
相关概念视频
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.2K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
870
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
870
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Mechanism
3.5K
The Hofmann and Curtius rearrangement reactions can be applied to synthesize primary amines from carboxylic acid derivatives such as amides and acyl azides. In the Hofmann rearrangement, a primary amide undergoes deprotonation in the presence of a base, followed by halogenation to generate an N-haloamide. A second proton abstraction produces a stabilized anionic species, which rearranges to an isocyanate intermediate via an alkyl group migration from the carbonyl carbon to the neighboring...
3.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
593
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
593
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
806
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
806


